Payment overview · 2025
General Payments
$1,065.23
60 reported records · 14 companies
Healthcare provider profile · identity verified
William P Newman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HARVEY, LA · NPI 1316906837
Verified facts
What the public records show
CMS Open Payments records show William P Newman, MD received $1,065.23 in general payments during 2025 across 60 reported records.
ABBVIE INC. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $256.64 | 24.1% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $215.17 | 20.2% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $143.00 | 13.4% | 11 | 2025 |
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $111.03 | 10.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.63 | 8.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.04 | 7.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.02 | 5.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.28 | 1.9% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.18 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.17 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.68 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.00 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.41 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.98 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,065.23 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $145.66 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $143.00 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $143.00 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $128.49 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $113.03 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $113.03 | 5 | 2025 |
Source payment records
|
|||||
| Altis Normalized: altis |
Device | COLOPLAST CORP | $111.03 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $87.00 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $85.63 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $80.78 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $64.36 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $58.98 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.61 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.41 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.95 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.28 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 127 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 116 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 170 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
116 | 40 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
170 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 794 | 216 |
| Atorvastatin Calcium | Atorvastatin Calcium | 694 | 203 |
| Losartan Potassium | Losartan Potassium | 468 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 115 |
| Alprazolam | Alprazolam | 426 | 67 |
| Metformin Hcl | Metformin Hcl | 412 | 112 |
| Omeprazole | Omeprazole | 393 | 121 |
| Gabapentin | Gabapentin | 348 | 108 |
| Meloxicam | Meloxicam | 333 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 321 | 96 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 316 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 298 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 294 | 87 |
| Tramadol Hcl | Tramadol Hcl | 281 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 78 |
| Lisinopril | Lisinopril | 261 | 71 |
| Sertraline Hcl | Sertraline Hcl | 248 | 64 |
| Trazodone Hcl | Trazodone Hcl | 235 | 82 |
| Duloxetine Hcl | Duloxetine Hcl | 222 | 64 |
| Glipizide | Glipizide | 219 | 62 |
| Montelukast Sodium | Montelukast Sodium | 213 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 58 |
| Allopurinol | Allopurinol | 200 | 57 |
| Clonazepam | Clonazepam | 194 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 50 |
| Lovastatin | Lovastatin | 176 | 48 |
| Mounjaro | Tirzepatide | 170 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 164 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 157 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 141 | 37 |
| Azithromycin | Azithromycin | 128 | 105 |
| Eliquis | Apixaban | 127 | 28 |
| Lorazepam | Lorazepam | 126 | 30 |
| Simvastatin | Simvastatin | 120 | 29 |
| Linzess | Linaclotide | 116 | 40 |
| Buspirone Hcl | Buspirone Hcl | 114 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 36 |
| Ezetimibe | Ezetimibe | 113 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 34 |
| Jardiance | Empagliflozin | 103 | 22 |
| Furosemide | Furosemide | 99 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 97 | 78 |
| Aripiprazole | Aripiprazole | 93 | 26 |
| Azelastine Hcl | Azelastine Hcl | 91 | 40 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 90 | 52 |
| Potassium Chloride | Potassium Chloride | 87 | 29 |
| Carvedilol | Carvedilol | 86 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 29 |
| Methylprednisolone | Methylprednisolone | 84 | 76 |
| Pregabalin | Pregabalin | 84 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 31 |
| Temazepam | Temazepam | 83 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 28 |
| Metformin Hcl Er | Metformin Hcl | 82 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 22 |
| Donepezil Hcl | Donepezil Hcl | 80 | 23 |
| Ondansetron Odt | Ondansetron | 75 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 74 | 64 |
| Meclizine Hcl | Meclizine Hcl | 74 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | 15 |
| Valsartan | Valsartan | 73 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 13 |
| Diazepam | Diazepam | 70 | 24 |
| Atenolol | Atenolol | 69 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 19 |
| Memantine Hcl | Memantine Hcl | 65 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 64 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 22 |
| Famotidine | Famotidine | 61 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 52 | suppressed |
| Celecoxib | Celecoxib | 51 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | 14 |
| Glipizide Er | Glipizide | 50 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 31 |
| Ozempic | Semaglutide | 47 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | 13 |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 20 |
| Estradiol | Estradiol | 40 | 14 |
| Ketoconazole | Ketoconazole | 40 | 11 |
| Megestrol Acetate | Megestrol Acetate | 39 | 14 |
| Spironolactone | Spironolactone | 39 | 13 |
| Finasteride | Finasteride | 38 | 13 |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Ramipril | Ramipril | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Mupirocin | Mupirocin | 34 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Nystatin | Nystatin | 32 | 15 |
| Prednisone | Prednisone | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 19 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 12 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Indomethacin | Indomethacin | 27 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Ciclopirox | Ciclopirox | 26 | 12 |
| Fluconazole | Fluconazole | 26 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 24 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Ofloxacin | Ofloxacin | 20 | 18 |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 12 |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,065.23 · 60 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Altis, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error